跳到正文
原文
Medical Xpress·· 2026-10-20AI 评分52

专家观点:ADHD药物有望缓解围绝经期脑雾,但需更大研究验证

ADHD medications offer promise in managing menopausal brain fog

AI 导读

一项在2026年绝经期协会年会上发表的围绝经期执行功能障碍范围综述显示,ADHD药物(利他林/托莫西汀)可显著改善女性自评的执行功能,但未能提升工作记忆等客观认知指标。研究人员指出,虽然这些药物可能通过调节儿茶酚胺通路缓解“脑雾”主观症状,但目前尚无FDA批准的药理干预手段,且需要更大规模研究确认其在该用途下的安全性与有效性,因此暂不推荐作为治疗选择。

正文
forgetful
Credit: Unsplash/CC0 Public Domain

An estimated 44% to 60% of perimenopausal women report cognitive changes like forgetfulness and trouble concentrating—also known as brain fog. Despite the effect of these symptoms on quality of life and productivity, there is currently no FDA-approved pharmacological intervention.

A new review suggests that ADHD medications may help. Study results were presented at the 2026 Annual Meeting of The Menopause Society in San Diego Oct. 20–24, 2026.

The menopause transition is characterized by a significant decline and fluctuation in estrogen, which mediates catecholaminergic signaling within the prefrontal cortex. This neurobiological shift results in brain fog, involving quantifiable deficits in working memory, attentional control and processing speed that mirror the core symptom domains of ADHD.

Researchers undertook a scoping review to better understand the utility of ADHD medications as a novel, targeted therapy to improve executive dysfunction experienced during the perimenopause period. They specifically looked at original research studies involving ADHD medications (lisdexamfetamine, or LDX, and atomoxetine, or ATX) and their effects on cognition and ADHD symptom severity.

Inclusion criteria included biological women 45–60 years of age with a last menstrual period less than 10 years ago. Exclusion criteria included transgender women, disordered sleep, surgical menopause, primary ovarian insufficiency, premature or early menopause, and previous or current cancer diagnosis.

The researchers found preliminary evidence that both stimulant (LDX) and nonstimulant (ATX) medications significantly improve self-reported executive function. This was shown by a marked reduction in total Brown Attention Deficit Disorder Scale (BADDS) scores compared to placebo. Neuroimaging data from a subset of women taking LDX further support these findings.

Despite these improvements in subjective "brain fog," these medications had little to no significant impact on objective cognitive measures, such as tests of working memory and sustained attention.

Furthermore, while cross-sectional data suggest a positive correlation between ADHD symptom severity and the intensity of menopause symptoms, findings regarding the impact of a formal ADHD diagnosis on somatic and psychological complaints remain inconsistent.

Based on these results, the researchers concluded that these ADHD medications may improve subjective executive function, but not cognition, by modulating catecholaminergic pathways that are often disrupted during the menopause transition. Moreover, cross-sectional evidence suggests that baseline ADHD symptom severity is associated with greater perimenopausal symptom burden.

These findings could open the door to a nonhormone therapeutic option for addressing perimenopausal executive dysfunction. However, larger studies are needed to confirm whether these medications are safe and effective for this use before they can be recommended as a treatment option.

"Many women at perimenopause notice changes in focus, memory and organization that look a lot like ADHD, and the two can be hard to tell apart. Our review found early signs that ADHD medications may help women feel more on top of their daily lives. While it's too early to recommend these medications, a quick screen for ADHD symptoms is a simple step that could help women get the right care," says Jennifer Tat, lead author from the University of Tennessee Health Science Center in Memphis.

Details of the study will be discussed as part of the presentation titled "Brain Fog or ADHD? Executive Dysfunction in Perimenopause: A Scoping Review of the Role of ADHD Medications."

"For most women, brain fog at menopause is a temporary condition that does not lead to permanent cognitive changes or dementia. However, it can last long enough to disrupt work and daily routines and cause significant stress and anxiety. That's why studies like this are important in helping to identify additional options for symptoms," says Dr. Stephanie Faubion, medical director for The Menopause Society.

More information

Brain Fog or ADHD? Executive Dysfunction in Perimenopause: A Scoping Review of the Role of ADHD Medications

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: ADHD medications offer promise in managing menopausal brain fog (2026, October 20) retrieved 20 October 2026 from https://medicalxpress.com/news/2026-10-adhd-medications-menopausal-brain-fog.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com